KOL Corner: Amy Ellis Discusses Value-Based Cancer Rehab With Amanda Hodges

Amy Ellis, director of quality and value-based care at Northwest Medical Specialties, and Amanda Hodges, director of implementation for ReVital Cancer Rehabilitation, who acts as a bridge between the oncology world and the rehabilitation world, discuss overcoming barriers in practices to help patients with cancer get the rehab care they need, how patients with cancer can benefit from rehab, and defining value.

Related Videos

Related Content

Advertisement

June 12th 2025

Mitomycin Intravesical Solution Gains FDA Approval for Recurrent Low-Grade NMIBC

Giuliana Grossi

The FDA approved mitomycin intravesical solution (Zusduri) for patients with recurrent low-grade intermediate risk non–muscle-invasive bladder cancer (NMIBC).

June 10th 2025

Blister Packs May Help Solve Medication Adherence Challenges and Lower Health Care Costs

Brooke McCormick Julia D. Lucaci, PharmD, MS

Julia Lucaci, PharmD, MS, of Becton, Dickinson and Company, discusses the benefits of blister packaging for chronic medications, advocating for payer incentives to boost medication adherence and improve health outcomes.

June 12th 2025

How Value-Based Care With Provider Enablement Improves Maternal and Infant Outcomes in Medicaid

Benjamin Howell, PhD, MPP Leah Ramirez, MS Kristin Austin, MPH Sara Varner, MPH Bryony Winn, MPhil Tiffany Inglis, MD

Supported value-based care improves prenatal care while reducing neonatal intensive care unit stays, preterm birth rates, low birth weight rates, and costs for mothers and infants.

June 3rd 2025

Managed Care Cast News Roundup: June 3, 2025

Giuliana Grossi

A quick roundup episode of major health policy developments, from shifting COVID-19 vaccine guidance and scientific publishing controversies to rising cancer care costs and the impact of oncology biosimilars.

June 10th 2025

Real-World Use of GLP-1s Yields Less Weight Loss Than Clinical Trials

Hayden E. Klein

Patients who remained on treatment, especially at higher doses or on tirzepatide, were more likely to achieve clinically meaningful weight loss and improved glycemic control.

June 10th 2025

Fixed-Duration SC Mosunetuzumab Shows 83% PFS at 1 Year in Untreated HTB Follicular Lymphoma

Mary Caffrey

Data presented at ASCO are the latest positive results for a subcutaneous version of this bispecific T-cell engager, which faces competition in follicular lymphoma.

Related Content

Advertisement

June 12th 2025

Mitomycin Intravesical Solution Gains FDA Approval for Recurrent Low-Grade NMIBC

Giuliana Grossi

The FDA approved mitomycin intravesical solution (Zusduri) for patients with recurrent low-grade intermediate risk non–muscle-invasive bladder cancer (NMIBC).

June 10th 2025

Blister Packs May Help Solve Medication Adherence Challenges and Lower Health Care Costs

Brooke McCormick Julia D. Lucaci, PharmD, MS

Julia Lucaci, PharmD, MS, of Becton, Dickinson and Company, discusses the benefits of blister packaging for chronic medications, advocating for payer incentives to boost medication adherence and improve health outcomes.

June 12th 2025

How Value-Based Care With Provider Enablement Improves Maternal and Infant Outcomes in Medicaid

Benjamin Howell, PhD, MPP Leah Ramirez, MS Kristin Austin, MPH Sara Varner, MPH Bryony Winn, MPhil Tiffany Inglis, MD

Supported value-based care improves prenatal care while reducing neonatal intensive care unit stays, preterm birth rates, low birth weight rates, and costs for mothers and infants.

June 3rd 2025

Managed Care Cast News Roundup: June 3, 2025

Giuliana Grossi

A quick roundup episode of major health policy developments, from shifting COVID-19 vaccine guidance and scientific publishing controversies to rising cancer care costs and the impact of oncology biosimilars.

June 10th 2025

Real-World Use of GLP-1s Yields Less Weight Loss Than Clinical Trials

Hayden E. Klein

Patients who remained on treatment, especially at higher doses or on tirzepatide, were more likely to achieve clinically meaningful weight loss and improved glycemic control.

June 10th 2025

Fixed-Duration SC Mosunetuzumab Shows 83% PFS at 1 Year in Untreated HTB Follicular Lymphoma

Mary Caffrey

Data presented at ASCO are the latest positive results for a subcutaneous version of this bispecific T-cell engager, which faces competition in follicular lymphoma.